Ubs Group Ag Savara Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Savara Inc stock. As of the latest transaction made, Ubs Group Ag holds 170,079 shares of SVRA stock, worth $544,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares

170,079

Previous 126,034 34.95%

Holding current value

$544,252

Previous $507,000 42.21%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $174,418 - $223,308	44,045 Added 34.95%	170,079 $721,000
Q2 2024 Aug 13, 2024	BUY	$3.66 - $5.34 $63,490 - $92,632	17,347 Added 15.96%	126,034 $507,000
Q1 2024 May 13, 2024	BUY	$4.19 - $5.59 $10,269 - $13,701	2,451 Added 2.31%	108,687 $541,000
Q4 2023 Feb 09, 2024	BUY	$3.18 - $4.9 $164,612 - $253,648	51,765 Added 95.03%	106,236 $499,000
Q3 2023 Nov 09, 2023	BUY	$2.97 - $3.88 $23,659 - $30,908	7,966 Added 17.13%	54,471 $205,000
Q2 2023 Aug 11, 2023	BUY	$1.69 - $3.24 $72,590 - $139,167	42,953 Added 1209.26%	46,505 $148,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.82 $5,051 - $8,902	3,157 Added 799.24%	3,552 $6,000
Q3 2022 Nov 10, 2022	SELL	$1.36 - $1.88 $11,686 - $16,154	-8,593 Reduced 95.61%	395 $1,000
Q2 2022 Aug 10, 2022	BUY	$1.1 - $1.58 $3,853 - $5,534	3,503 Added 63.87%	8,988 $14,000
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $5,344 - $6,922	5,090 Added 1288.61%	5,485 $8,000
Q4 2021 Feb 14, 2022	SELL	$1.04 - $1.34 $4,191 - $5,400	-4,030 Reduced 91.07%	395 $0
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $16,562 - $23,019	-14,036 Reduced 76.03%	4,425 $7,000
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.29 $2,162 - $3,279	-1,432 Reduced 7.2%	18,461 $31,000
Q1 2021 May 12, 2021	SELL	$1.17 - $2.33 $4,312 - $8,588	-3,686 Reduced 15.63%	19,893 $41,000
Q4 2020 Feb 11, 2021	BUY	$1.0 - $1.47 $23,002 - $33,812	23,002 Added 3986.48%	23,579 $27,000
Q3 2020 Nov 12, 2020	SELL	$1.09 - $2.21 $16,212 - $32,871	-14,874 Reduced 96.27%	577 $1,000
Q2 2020 Jul 31, 2020	SELL	$1.8 - $3.05 $8,449 - $14,316	-4,694 Reduced 23.3%	15,451 $38,000
Q1 2020 May 01, 2020	SELL	$1.91 - $4.08 $46,309 - $98,923	-24,246 Reduced 54.62%	20,145 $43,000
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $9,559 - $66,108	13,464 Added 43.53%	44,391 $199,000
Q3 2019 Nov 14, 2019	BUY	$2.16 - $3.2 $48,431 - $71,750	22,422 Added 263.63%	30,927 $82,000
Q1 2019 May 14, 2019	SELL	$6.71 - $8.6 $33,469 - $42,896	-4,988 Reduced 36.97%	8,505 $63,000
Q4 2018 Feb 14, 2019	SELL	$6.27 - $10.92 $248,179 - $432,235	-39,582 Reduced 74.58%	13,493 $102,000
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $382,475 - $469,253	36,461 Added 219.46%	53,075 $593,000
Q2 2018 Aug 14, 2018	BUY	$8.55 - $13.76 $17,595 - $28,318	2,058 Added 14.14%	16,614 $188,000
Q1 2018 May 15, 2018	BUY	$8.99 - $14.95 $119,099 - $198,057	13,248 Added 1012.84%	14,556 $133,000
Q4 2017 Feb 14, 2018	SELL	$8.26 - $16.76 $59,711 - $121,158	-7,229 Reduced 84.68%	1,308 $19,000
Q3 2017 Nov 14, 2017	BUY	$5.1 - $9.55 $43,513 - $81,480	8,532 Added 170640.0%	8,537 $80,000
Q2 2017 Aug 14, 2017	BUY	N/A	5	5 $0

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account